Xenon Pharmaceuticals (XENE) Misses Q1 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Xenon Pharmaceuticals (XENE) PT Raised to $8 at Jefferies Following New Epilepsy Asset
May 10, 2017 10:35 AM EDTJefferies raised its price target on Xenon Pharmaceuticals (NASDAQ: XENE) to $8.00 (from $7.00) while maintaining a Buy rating. The company added a new epilepsy asset, XEN1101, to their portfolio.
TV-45070 topline results are expected mid-2017. An IND for '901 is planned for 4Q17, and... More
